1. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients
- Author
-
David Back, Myra McClure, Lucy Garvey, Otto Erlwein, John Walsh, Ngaire Latch, Nicola Mackie, Laura Dickinson, Alan Winston, and George Scullard
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,Organophosphonates ,HIV Infections ,Pharmacology ,Emtricitabine ,Gastroenterology ,Deoxycytidine ,Drug Administration Schedule ,Young Adult ,Pharmacokinetics ,Internal medicine ,Raltegravir Potassium ,Medicine ,Humans ,Pharmacology (medical) ,Clinical significance ,Drug Interactions ,Tenofovir ,Darunavir ,Sulfonamides ,Ritonavir ,business.industry ,Adenine ,HIV Protease Inhibitors ,Middle Aged ,Raltegravir ,Confidence interval ,Pyrrolidinones ,Regimen ,Infectious Diseases ,Treatment Outcome ,HIV-1 ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
BackgroundNucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown.MethodsFourteen HIV-1-infected patients (age 21–55 years, 64% male) on stable cART with plasma HIV RNA ResultsNo statistically significant differences in pharmacokinetic parameters were observed between period 2 versus period 1. During period 3, darunavir GMR (95% confidence interval) values for trough and maximum plasma concentration (Ctroughand Cmax), area under the plasma concentration–time curve (AUC) and elimination half-life (t1/2) were 0.64 ng/ml (0.44–0.93), 1.05 ng/ ml (0.90–1.24), 0.92 ng h/ml (0.78–1.08) and 0.69 h (0.46–1.05), respectively, when compared with period 1. No statistically significant changes were observed in ritonavir or raltegravir pharmacokinetic parameters. Darunavir CtroughConclusionsDarunavir Ctroughis reduced by 36% when administered without tenofovir/emtricitabine in HIV-1 -infected patients. This interaction might be of clinical significance in the management of individuals with protease-resistant HIV viral isolates.
- Published
- 2010